Interdisciplinary approaches with coordinated teams of highly specialized professionals are the hallmark of patient care.
The Movement Disorders Division is an integral part of The Ohio State University Wexner Medical Center’s Neurological Institute. Through collaboration with major departments within the institute – Psychiatry, Neurosurgery, Physical Medicine and Rehabilitation, Neuroscience and Neurology – patients receive innovative treatment while researchers contribute to the international knowledge base of neurological disease and movement disorders.
Our health professionals belong to the Parkinson Study Group and the Huntington Study Group, national consortiums of academic centers that develop and carry out clinical trials examining new therapies for movement disorders. The division is the only central Ohio site that offers DaT scans to aid in diagnosing Parkinson’s disease and essential tremor, and Duopa infusion therapy for patients with advanced Parkinson’s disease. For 15 consecutive years, our Huntington’s disease program has received Center of Excellence status from the Huntington’s Disease Society of America.
The division comprises the Madden Center for Parkinson’s Disease and Related Disorders, where patients benefit from high-quality treatment for Parkinson’s disease, essential tremor, dystonia, Huntington’s disease and other movement disorders. Interdisciplinary approaches with coordinated teams of highly specialized professionals are the hallmark of patient care. Treatment strategies facilitate deep brain stimulation for patients with Parkinson’s disease, essential tremor and dystonia, as well as individualized physical therapy and rehabilitation services for mobility issues and neuropsychiatric care for the cognitive and behavioral issues that may accompany movement disorders.
Gene therapy transforms introvert back into artist
Parkinson's left Gary feeling frozen. Gene therapy helped him pick up the torch
Can a blood pressure medication help Parkinson's patients?
Dr. Park is exploring the potential for isradipine to soothe the symptoms of patients with early-stage Parkinson's